Delivering reduced hands-on time, more consistent results and higher sample throughout
Oxford, UK, 24th September.
OGT, a leading global provider of genomic research and diagnostic solutions today unveiled next-generation sequencing (NGS) automation capabilities across its SureSeq™ NGS portfolio, compatible with the Hamiton NGS STAR Line. The latest advancement in OGT’s ongoing SureSeq investment, these automated workflows help laboratories optimise resources and deliver turnaround time targets.
Rising sample volumes are putting clinical research labs under pressure. Maintaining consistent…
Amsbio announce a new partnership with Atelerix to introduce its patented hydrogel technology for the room-temperature storage and transportation of living cells, tissues, organoids and viruses.
Preserving cell functionality during storage and transportation is challenging for cell-based therapies as cryopreservation methods can compromise cell viability and functionality. The novel hypothermic hydrogel technology, available from Amsbio, offers a revolutionary alternative, addressing many of the issues associated with cryopreservation.
This seaweed-derived hydrogel forms a protective…
New service brings senior regulatory expertise into the early development window, when strategic decisions can have the greatest impact.
DLRC, an award-winning global regulatory and market access consultancy that supports the development and licensing of pharmaceutical, biotech, advanced therapy, and medtech products worldwide, launches Regulatory Spark, a new fixed-fee, fast-turnaround service created for early-stage innovators.
Regulatory Spark is designed to help founder-led biotech companies, scientific founders, academic spinouts, and tech transfer teams understand their likely route to…
Barry Callebaut, the world’s leading manufacturer of high-quality chocolate and cocoa solutions, has moved into Colworth Science Park’s food tech incubator Gastronomica.
Gastronomica is a home for ambitious food-tech businesses advancing the future of food, enabling innovators and industry leaders to scale ideas, tackle global food shortages, and drive sustainable solutions.
Barry Callebaut has moved to the site to bolster its long-term presence at Colworth Science Park, home to The Magnum Ice Cream Company (TMICC). The move reinforces Barry Callebaut’s commitment to the local innovation…
Beacon for rare diseases, a Cambridge-based charity, has just launched Rare Insights – a ground-breaking study exploring the value and impact of rare disease patient groups, alongside the challenges they face.
Patient groups are often the first port-of-call for newly diagnosed patients with a rare disease. By providing much-needed support to individuals with rare diseases and their families, they become a lifeline, frequently advocating for research and helping to shape policies that put patients at their heart.
Despite their vital work for those with rare diseases, the value of patient…
Former Olink Proteomics President brings extensive life-science tools leadership experience, having helped lead Olink through its $3.1 billion acquisition by Thermo Fisher Scientific
Co-founder and former CEO Dr Michael Chen transitions to Chief Scientific and Business Officer
Cambridge, UK, and Boston, MA, USA, 22 September 2026: Nuclera, the biotechnology company enabling access to innovative protein technologies, today announced the appointment of Carl Raimond as Chief Executive Officer, effective immediately. Dr Michael Chen, Nuclera’s co-founder and former CEO, transitions to the role…
Global drug development consultancy Boyds has reported robust revenue growth for the financial year ending March 2026, despite the slowdown in the global biotech and pharma markets.
Established in 2005, Boyds provides specialist consultancy services to an international client base, supporting the development of new, cutting-edge medicines and medical devices for patient benefit.
By leveraging its specialist clinical and regulatory expertise in novel medicinal products including cell and gene therapy development, Boyds has successfully navigated uncertainty across its clients’ markets, which…
LONDON, UK; MADRID, Spain; and SHORT HILLS, NJ – September 16, 2026 – Coulter Partners, the global advisor building leadership teams for Health, Science and Technology innovation businesses, today announces the appointment of Carlos Gómez-Arnau, Doug Roberts, and Stuart Penney as Client Partners. These strategic hires further strengthen the firm's international presence and reinforce its commitment to supporting clients across key healthcare, life sciences, and biotechnology markets.The appointments expand Coulter Partners' capabilities across Europe and North America, including the…
Peptide drug discovery is the process of designing, synthesising, testing and optimising peptide molecules to investigate biological targets or develop therapeutic candidates. Depending on the programme, peptides can be used for target validation, screening, structure-activity relationship (SAR) studies, optimisation and therapeutic development.
Peptides occupy a distinctive chemical and pharmacological space between small molecules and larger biologics, combining high-affinity target recognition with substantial scope for sequence-level optimisation.
It provides a powerful route to…
Download the UK Life Sciences Innovation Signals Report
The UK life sciences sector continues to attract investment, strengthen research capabilities and advance scientific innovation. The key question facing the market is no longer whether innovation is being created. It is whether innovation can be converted into commercial growth, healthcare adoption and measurable patient impact.
https://www.frazierdeeter.co.uk/wp-content/uploads/2026/08/UK-Life-Scie…
The UK Life Sciences Innovation Signals report examines the latest data across three critical areas shaping the sector’s future:
- Capital…